308 related articles for article (PubMed ID: 24982504)
1. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.
Cutler C; Logan B; Nakamura R; Johnston L; Choi S; Porter D; Hogan WJ; Pasquini M; MacMillan ML; Hsu JW; Waller EK; Grupp S; McCarthy P; Wu J; Hu ZH; Carter SL; Horowitz MM; Antin JH
Blood; 2014 Aug; 124(8):1372-7. PubMed ID: 24982504
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
[TBL] [Abstract][Full Text] [Related]
3. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
4. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.
Khimani F; Kim J; Chen L; Dean E; Rizk V; Betts B; Nishihori T; Locke F; Mishra A; Perez L; Ayala E; Kharfan-Dabaja M; Nieder M; Fernandez H; Anasetti C; Pidala J
Bone Marrow Transplant; 2017 Jul; 52(7):1003-1009. PubMed ID: 28368376
[TBL] [Abstract][Full Text] [Related]
5. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.
Kharfan-Dabaja MA; Parody R; Perkins J; Lopez-Godino O; Lopez-Corral L; Vazquez L; Caballero D; Falantes J; Shapiro J; Ortí G; Barba P; Valcárcel D; Esquirol A; Martino R; Piñana JL; Solano C; Tsalatsanis A; Pidala J; Anasetti C; Perez-Simón JA
Bone Marrow Transplant; 2017 Mar; 52(3):438-444. PubMed ID: 27819684
[TBL] [Abstract][Full Text] [Related]
7. Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.
Abu Zaid M; Wu J; Wu C; Logan BR; Yu J; Cutler C; Antin JH; Paczesny S; Choi SW
Blood; 2017 Jan; 129(2):162-170. PubMed ID: 27827824
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
Labrador J; López-Corral L; López-Godino O; Vázquez L; Cabrero-Calvo M; Pérez-López R; Díez-Campelo M; Sánchez-Guijo F; Pérez-López E; Guerrero C; Alberca I; Del Cañizo MC; Pérez-Simón JA; González-Porras JR; Caballero D
Bone Marrow Transplant; 2014 May; 49(5):684-90. PubMed ID: 24566710
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
[TBL] [Abstract][Full Text] [Related]
10. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.
Cutler C; Li S; Ho VT; Koreth J; Alyea E; Soiffer RJ; Antin JH
Blood; 2007 Apr; 109(7):3108-14. PubMed ID: 17138818
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J
Haematologica; 2016 Nov; 101(11):1417-1425. PubMed ID: 27662016
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.
Nakamae H; Nakane T; Okamura H; Koh H; Nakashima Y; Hirose A; Nakamae M; Nishimoto M; Kuno M; Makuuchi Y; Harada N; Takakuwa T; Hino M
Int J Hematol; 2022 Jan; 115(1):77-86. PubMed ID: 34586587
[TBL] [Abstract][Full Text] [Related]
14. Minimum-Dose, Short-Term Methotrexate With Tacrolimus for Graft-vs-Host Disease Prophylaxis Following Unrelated Cord Blood Transplantation in Adults: A Retrospective Analysis at a Single Institution.
Iino M; Sato T; Sakamoto Y
Transplant Proc; 2021; 53(1):396-404. PubMed ID: 33308840
[TBL] [Abstract][Full Text] [Related]
15. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation.
Mirza AS; Tandon A; Jenneman D; Cao S; Brimer T; Kumar A; Kidd M; Khimani F; Faramand R; Mishra A; Liu H; Nishihori T; Perez L; Lazaryan A; Bejanyan N; Nieder M; Anasetti C; Pidala J; Elmariah H
Transplant Cell Ther; 2022 Apr; 28(4):185.e1-185.e7. PubMed ID: 35017119
[TBL] [Abstract][Full Text] [Related]
16. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.
Pulsipher MA; Langholz B; Wall DA; Schultz KR; Bunin N; Carroll WL; Raetz E; Gardner S; Gastier-Foster JM; Howrie D; Goyal RK; Douglas JG; Borowitz M; Barnes Y; Teachey DT; Taylor C; Grupp SA
Blood; 2014 Mar; 123(13):2017-25. PubMed ID: 24497539
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
[TBL] [Abstract][Full Text] [Related]
18. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.
Kanate AS; Hari PN; Pasquini MC; Visotcky A; Ahn KW; Boyd J; Guru Murthy GS; Rizzo JD; Saber W; Drobyski W; Michaelis L; Atallah E; Carlson KS; D'Souza A; Fenske TS; Cumpston A; Bunner P; Craig M; Horowitz MM; Hamadani M
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1295-1302. PubMed ID: 28412518
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.
Antin JH; Kim HT; Cutler C; Ho VT; Lee SJ; Miklos DB; Hochberg EP; Wu CJ; Alyea EP; Soiffer RJ
Blood; 2003 Sep; 102(5):1601-5. PubMed ID: 12730113
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention.
Hamilton BK; Rybicki LA; Li H; Lucas T; Corrigan D; Kalaycio M; Sobecks R; Hanna R; Rotz SJ; Dean RM; Gerds AT; Jagadeesh D; Brunstein C; Sauter CS; Copelan EA; Majhail NS
Blood Adv; 2023 Aug; 7(16):4505-4513. PubMed ID: 37352262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
